3-甲氧基-2-苯基咪唑并[1,2-b]哒嗪对结核分枝杆菌和海洋分枝杆菌具有高活性。

IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL
Kyle D. Farrell , Yamin Gao , Deborah A. Hughes , Robin Henches , Zhengchao Tu , Michael V. Perkins , Tianyu Zhang , Craig L. Francis
{"title":"3-甲氧基-2-苯基咪唑并[1,2-b]哒嗪对结核分枝杆菌和海洋分枝杆菌具有高活性。","authors":"Kyle D. Farrell ,&nbsp;Yamin Gao ,&nbsp;Deborah A. Hughes ,&nbsp;Robin Henches ,&nbsp;Zhengchao Tu ,&nbsp;Michael V. Perkins ,&nbsp;Tianyu Zhang ,&nbsp;Craig L. Francis","doi":"10.1016/j.ejmech.2023.115637","DOIUrl":null,"url":null,"abstract":"<div><p>A series of 3-methoxy-2-phenylimidazo[1,2-<em>b</em>]pyridazine derivatives which were highly active against autoluminescent <em>Mycobacterium tuberculosis</em> (Mtb) and <em>Mycobacterium marinum</em> (Mm) in an <em>in vitro</em> assay were identified. SAR analysis showed that the most active compounds, which included a phenyl group bearing fluoro substituent(s) at C2, a methoxy function at C3, and a benzyl-heteroatom moiety at C6, exhibited <em>in vitro</em> MIC<sub>90</sub> values generally around 0.63–1.26 μM against Mtb and Mm. However, these compounds were inactive against Mtb <em>in vivo</em> (mice), and investigations revealed very short metabolic half-lives (&lt;10 min) when incubated with mouse liver microsomes. Multiple observations of side products produced from oxidative cleavage of the imidazole moiety during the chemical synthesis work suggested that this is a likely metabolic pathway leading to the lack of observed activity <em>in vivo</em>.</p></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"259 ","pages":"Article 115637"},"PeriodicalIF":6.0000,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0223523423006037/pdfft?md5=2d6df61a1fec7e86f4b11a55e07df197&pid=1-s2.0-S0223523423006037-main.pdf","citationCount":"0","resultStr":"{\"title\":\"3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum\",\"authors\":\"Kyle D. Farrell ,&nbsp;Yamin Gao ,&nbsp;Deborah A. Hughes ,&nbsp;Robin Henches ,&nbsp;Zhengchao Tu ,&nbsp;Michael V. Perkins ,&nbsp;Tianyu Zhang ,&nbsp;Craig L. Francis\",\"doi\":\"10.1016/j.ejmech.2023.115637\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A series of 3-methoxy-2-phenylimidazo[1,2-<em>b</em>]pyridazine derivatives which were highly active against autoluminescent <em>Mycobacterium tuberculosis</em> (Mtb) and <em>Mycobacterium marinum</em> (Mm) in an <em>in vitro</em> assay were identified. SAR analysis showed that the most active compounds, which included a phenyl group bearing fluoro substituent(s) at C2, a methoxy function at C3, and a benzyl-heteroatom moiety at C6, exhibited <em>in vitro</em> MIC<sub>90</sub> values generally around 0.63–1.26 μM against Mtb and Mm. However, these compounds were inactive against Mtb <em>in vivo</em> (mice), and investigations revealed very short metabolic half-lives (&lt;10 min) when incubated with mouse liver microsomes. Multiple observations of side products produced from oxidative cleavage of the imidazole moiety during the chemical synthesis work suggested that this is a likely metabolic pathway leading to the lack of observed activity <em>in vivo</em>.</p></div>\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":\"259 \",\"pages\":\"Article 115637\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2023-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0223523423006037/pdfft?md5=2d6df61a1fec7e86f4b11a55e07df197&pid=1-s2.0-S0223523423006037-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0223523423006037\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523423006037","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

在体外试验中鉴定了一系列对结核分枝杆菌(Mtb)和海洋分枝杆菌(Mm)具有高活性的3-甲氧基-2-苯基咪唑并[1,2-b]哒嗪衍生物。SAR分析表明,最具活性的化合物,包括C2处带有氟取代基的苯基、C3处的甲氧基官能团和C6处的苄基杂原子部分,在体外对Mtb和Mm的MIC90值通常约为0.63-1.26μM。然而,这些化合物在体内对Mtb(小鼠)无活性,研究显示代谢半衰期非常短(
本文章由计算机程序翻译,如有差异,请以英文原文为准。

3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum

3-Methoxy-2-phenylimidazo[1,2-b]pyridazines highly active against Mycobacterium tuberculosis and Mycobacterium marinum

A series of 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivatives which were highly active against autoluminescent Mycobacterium tuberculosis (Mtb) and Mycobacterium marinum (Mm) in an in vitro assay were identified. SAR analysis showed that the most active compounds, which included a phenyl group bearing fluoro substituent(s) at C2, a methoxy function at C3, and a benzyl-heteroatom moiety at C6, exhibited in vitro MIC90 values generally around 0.63–1.26 μM against Mtb and Mm. However, these compounds were inactive against Mtb in vivo (mice), and investigations revealed very short metabolic half-lives (<10 min) when incubated with mouse liver microsomes. Multiple observations of side products produced from oxidative cleavage of the imidazole moiety during the chemical synthesis work suggested that this is a likely metabolic pathway leading to the lack of observed activity in vivo.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信